Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Reuters

Nov 13, 2025

<a href="https://laohu8.com/S/EVOK">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Overview

Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln
Company to be acquired by QOL Medical for $11.00 per share
Gimoti patent extended to November 2038, ensuring exclusivity

Outlook

Company expects acquisition by QOL Medical to close in Q4 2025
Company anticipates expanded distribution through new pharmacy relationships
Company believes acquisition will enhance growth potential under new leadership

Result Drivers

SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships
EXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distribution

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.45
Q3 Net Income		-$1.20 mln
Q3 Operating Expenses		$5.40 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nGNX80pkz3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583556248"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583556248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583556248?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583556248","market":"fut","top_or_hot":-1,"title":"Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title></head><body><p><span>Overview</span></p><ul><li><p>Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln</p></li><li><p>Company to be acquired by QOL Medical for $11.00 per share</p></li><li><p>Gimoti patent extended to November 2038, ensuring exclusivity</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects acquisition by QOL Medical to close in Q4 2025</p></li><li><p>Company anticipates expanded distribution through new pharmacy relationships</p></li><li><p>Company believes acquisition will enhance growth potential under new leadership</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships</p></li><li><p>EXPANDED ACCESS - New pharmacy relationships with <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> and Brentwood Pharmacy enhance distribution</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX80pkz3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title></head><body><p><span>Overview</span></p><ul><li><p>Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln</p></li><li><p>Company to be acquired by QOL Medical for $11.00 per share</p></li><li><p>Gimoti patent extended to November 2038, ensuring exclusivity</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects acquisition by QOL Medical to close in Q4 2025</p></li><li><p>Company anticipates expanded distribution through new pharmacy relationships</p></li><li><p>Company believes acquisition will enhance growth potential under new leadership</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships</p></li><li><p>EXPANDED ACCESS - New pharmacy relationships with <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> and Brentwood Pharmacy enhance distribution</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX80pkz3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0GH:1","article_id":"2583556248","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583556248","pubTimestamp":1763036065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evoke Pharma Q3 sales rise 61%, expects QOL Medicalacquisition to close in Q4 2025OverviewEvoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mlnCompany to be acquired by QOL Medical for $11.00 per","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EVOK":"Evoke Pharma Inc."},"translate_title":"Evoke Pharma第三季度销售额增长61%，预计QOL Medical收购将于2025年第四季度完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":0.9},"content_text":"Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025OverviewEvoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mlnCompany to be acquired by QOL Medical for $11.00 per shareGimoti patent extended to November 2038, ensuring exclusivityOutlookCompany expects acquisition by QOL Medical to close in Q4 2025Company anticipates expanded distribution through new pharmacy relationshipsCompany believes acquisition will enhance growth potential under new leadershipResult DriversSALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnershipsEXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distributionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.45Q3 Net Income-$1.20 mlnQ3 Operating Expenses$5.40 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Press Release: ID:nGNX80pkz3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}